Loading...
Loading...
LIXT| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 1,632.6K |
| Operating I/L | -1,632.6K |
| Other Income/Expense | 1.3K |
| Interest Income | 7.0K |
| Pretax | -1,631.3K |
| Income Tax Expense | -5.2K |
| Net Income/Loss | -1,626.1K |
Lixte Biotechnology Holdings, Inc. is a drug discovery company specializing in biomarker technology to identify enzyme targets for serious common diseases. It focuses on developing inhibitors of protein phosphatases, used alone or in combination with other agents, for pre-clinical and clinical development. The company's drug series, LB-100 and LB-200, target cancers, vascular and metabolic diseases, chronic hereditary diseases, and neurodegenerative diseases. Lixte has clinical trial research agreements with Moffitt Cancer Center and Research Institute Hospital Inc., and collaborations with the Spanish Sarcoma Group, Netherlands Cancer Institute, and Oncode Institute.
